Wegovy (semaglutide 2.4mg) Letter of Medical Necessity
Wegovy (semaglutide 2.4mg) prior authorization requires meticulous BMI and comorbidity documentation. Many plans categorically exclude weight-loss agents, requiring a benefit exception process. For BMI documentation tactics and payer-by-payer rules, see our GLP-1 Prior Authorization Guide.
FDA-Approved Indications
- ● chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity
- ● pediatric obesity ≥12 years
Why Wegovy Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. BMI criteria not documented
- 2. Comorbidity not documented
- 3. Lifestyle intervention trial not on file
- 4. Plan excludes weight-loss medications
- 5. Off-label for cosmetic weight loss
What to Include in a Wegovy Letter of Medical Necessity
Document baseline BMI, weight-related comorbidities (T2DM, hypertension, dyslipidemia, OSA, CVD), prior lifestyle intervention duration and outcomes, prior pharmacotherapy trials, and SELECT trial CV risk reduction data when applicable.
Key clinical evidence to cite:
- ✓ STEP 1-8 trials
- ✓ SELECT cardiovascular outcomes trial showing 20% MACE reduction
- ✓ OASIS oral semaglutide comparison
Relevant guidelines:
- 📖 AACE/ACE 2023 Obesity Algorithm
- 📖 AHA/ACC 2023 Obesity Statement
- 📖 Endocrine Society 2015 Obesity Guideline
Wegovy Prior Authorization Criteria
Standard criteria across major US payers for Wegovy. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Lifestyle intervention trial not on file
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Wegovy
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Wegovy Prior Authorization FAQ
Why was my Wegovy prior authorization denied?
The most common denial reasons for Wegovy are: BMI criteria not documented; Comorbidity not documented; Lifestyle intervention trial not on file; Plan excludes weight-loss medications; Off-label for cosmetic weight loss.
What should a Wegovy Letter of Medical Necessity include?
Document baseline BMI, weight-related comorbidities (T2DM, hypertension, dyslipidemia, OSA, CVD), prior lifestyle intervention duration and outcomes, prior pharmacotherapy trials, and SELECT trial CV risk reduction data when applicable.
Which payers cover Wegovy?
Wegovy is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, CVS Caremark, though formulary tier and prior authorization criteria vary.